Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

The traditional approach to the treatment of advanced non-small cell lung cancer (NSCLC) relied on the uniform use of cytotoxic chemotherapy. Over the last eight years, this paradigm of care has been shifting towards the use of molecularly targeted agents. Epidermal growth factor receptor (EGFR) mut...

Full description

Bibliographic Details
Main Authors:	David E. Dawe, Peter M. Ellis
Format:	Article
Language:	English
Published:	MDPI AG 2012-09-01
Series:	Journal of Personalized Medicine
Subjects:	personalized medicine non-small cell lung cancer delivery of healthcare molecular targeted therapy erlotinib gefitinib crizotinib epidermal growth factor receptor
Online Access:	http://www.mdpi.com/2075-4426/2/3/77

Similar Items

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
by: Bai H, et al.
Published: (2017-04-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
by: Preenumol Thomas, et al.
Published: (2019-01-01)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
by: Yang CJ, et al.
Published: (2016-03-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
by: Wu JY, et al.
Published: (2016-10-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)

Retreatment with Epidermal Growth Factor Receptor Inhibitor After Initial Failure in Advanced Non-small Cell Lung Cancer
by: Tongtong AN, et al.
Published: (2011-03-01)

Maintenance therapies for non small cell lung cancer
by: Normand eBlais, et al.
Published: (2014-08-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

Four Cases of Interstitial Lung Disease Induced by Erlotinib  and A Review of the Literatures
by: Xiaoling WU, et al.
Published: (2012-08-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
by: Wenxiong Zhang, et al.
Published: (2018-08-01)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
by: Genovefa Polychronidou, et al.
Published: (2013-03-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
by: Ajaz Bulbul, et al.
Published: (2018-04-01)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015-03-01)

Research progress in the influence of EGFR genovariation on the clinical efficacy of gefitinib treatment of non-small cell lung cancer
by: Yang Wang, et al.
Published: (2018-02-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
by: Qian J, et al.
Published: (2020-05-01)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
by: Marc-Eric Halatsch, et al.
Published: (2012-05-01)

Correlation between DAPK Promoter Methylation and Gefitinib Sensitivity in Non-small Cell Lung Cancer
by: Weiqin Wu, et al.
Published: (2013-12-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

TKI Resistance for T790M Mutation
by: Hong WANG, et al.
Published: (2015-04-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
by: Abdul-Rahman Jazieh, et al.
Published: (2013-01-01)

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
by: Suzumura Tomohiro, et al.
Published: (2012-12-01)

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
by: Ya Gao, et al.
Published: (2018-12-01)

Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach
by: Young Rae Kim, et al.
Published: (2019-01-01)

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment
by: Yasuhiro Chikaishi, et al.
Published: (2014-02-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Effect and Mechanism of Gefitinib Inhibition on Non-small Cell Lung Cancer  Radiosensitivity of HCC827 and H358 Cell Lines
by: Ziye GAO, et al.
Published: (2012-06-01)

Cannot write session to /tmp/vufind_sessions/sess_g7q7eddm6iv8ed15fdc3hqk63h